IPOs and Secondaries
IPOs and Secondaries Articles
Digicel Group expects to price approximately 124 million shares in the range of $13 to $16 for its initial public offering.
Published:
The CPI Card Group initial public offering of more than 17 million shares is expected to price in the range of $16 to $18.
Published:
Weatherford International said Monday evening that it has chosen not to offer more shares after all.
Published:
Last Updated:
Performance Food Group expects to price 14.5 million shares in the range of $22 to $25 for its initial public offering.
Published:
Edge Therapeutics is offering more than 5 million shares in its initial public offering in an expected price range of $14 to $16 apiece.
Published:
Surgery Partners has filed with the Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
NovoCure has made an updated filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Dave & Buster's Entertainment has filed with the U.S. Securities and Exchange Commission (SEC) for a secondary offering of 6 million shares.
Published:
Weatherford International announced Monday morning that the company will raise $1 billion in a combination of an underwritten public offerings of ordinary shares and mandatorily exchangeable...
Published:
Last Updated:
ThinkstockOf three new initial public offerings (IPOs) on the calendar last week, all three made it out the door and began trading publicly. The week’s proposed fourth new issue was a U.S. listing...
Published:
Last Updated:
Penumbra priced its initial public offering of 4 million shares at $30 per share on Thursday night, and the stock began trading Friday morning at $40.
Published:
Last Updated:
More than 4 million Mirna Therapeutics shares are being offered in its initial public offering, with a value of up to more than $80 million.
Published:
Civitas Solutions has filed with the U.S. Securities and Exchange Commission (SEC) for a secondary offering.
Published:
ThinkstockNabriva Therapeutics A.G. has filed an amended F-1 form with the U.S. Securities and Exchange Commission (SEC) regarding the anticipated price of its initial public offering (IPO) in the...
Published:
Last Updated:
This is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy.
Published: